S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

$10.99
+0.78 (+7.64%)
(As of 03/1/2024 ET)
Today's Range
$10.28
$11.22
50-Day Range
$6.28
$10.99
52-Week Range
$2.25
$11.22
Volume
1.25 million shs
Average Volume
633,661 shs
Market Capitalization
$680.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25

Fulcrum Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
2.4% Upside
$11.25 Price Target
Short Interest
Bearish
5.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Fulcrum Therapeutics in the last 14 days
Based on 31 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.27 out of 5 stars

Medical Sector

889th out of 950 stocks

Pharmaceutical Preparations Industry

417th out of 440 stocks


FULC stock logo

About Fulcrum Therapeutics Stock (NASDAQ:FULC)

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Stock Price History

FULC Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Earnings Preview: Fulcrum Therapeutics
FULC Mar 2024 11.000 call
Fulcrum Therapeutics Inc (FULC)
Fulcrum Therapeutics Inc FULC
See More Headlines
Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/03/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FULC
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.25
High Stock Price Target
$17.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+2.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-109,870,000.00
Net Margins
-3,470.05%
Pretax Margin
-3,470.05%

Debt

Sales & Book Value

Annual Sales
$2.81 million
Book Value
$3.80 per share

Miscellaneous

Free Float
60,387,000
Market Cap
$680.72 million
Optionable
Optionable
Beta
2.31
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Alexander C. Sapir (Age 57)
    CEO, President & Director
  • Dr. Bradley E. Bernstein M.D.
    Ph.D., Founder
  • Dr. Michael R. Green
    Founder
  • Dr. Rudolf Jaenisch M.D.
    Ph.D., Founder
  • Prof. Jeannie T. Lee M.D.
    Ph.D., Founder
  • Dr. Danny Reinberg
    Founder
  • Mr. Gregory Tourangeau
    Controller & Principal Accounting Officer
  • Dr. Jeffrey W. Jacobs Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Curtis G. Oltmans J.D. (Age 61)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Comp: $83.98k
  • Mr. Paul Bruno
    Senior Vice President of Business & Corporate Development














FULC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulcrum Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FULC shares.
View FULC analyst ratings
or view top-rated stocks.

What is Fulcrum Therapeutics' stock price target for 2024?

7 equities research analysts have issued 1 year price targets for Fulcrum Therapeutics' stock. Their FULC share price targets range from $6.00 to $17.00. On average, they anticipate the company's stock price to reach $11.25 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for FULC
or view top-rated stocks among Wall Street analysts.

How have FULC shares performed in 2024?

Fulcrum Therapeutics' stock was trading at $6.75 at the start of the year. Since then, FULC stock has increased by 62.8% and is now trading at $10.99.
View the best growth stocks for 2024 here
.

When is Fulcrum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our FULC earnings forecast
.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.07. The company had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.94 million. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 36.65% and a negative net margin of 3,470.05%. During the same period in the previous year, the company earned ($0.70) EPS.

What ETFs hold Fulcrum Therapeutics' stock?

ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Simplify Health Care ETF (PINK).

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

When did Fulcrum Therapeutics IPO?

(FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Who are Fulcrum Therapeutics' major shareholders?

Fulcrum Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (8.85%), Vanguard Group Inc. (4.08%), Vestal Point Capital LP (1.66%), Dimensional Fund Advisors LP (1.58%), Goldman Sachs Group Inc. (1.41%) and ADAR1 Capital Management LLC (1.03%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Greg Tourangeau, James A Geraghty, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould.
View institutional ownership trends
.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FULC) was last updated on 3/3/2024 by MarketBeat.com Staff